Pipeline

Advancing Best-in-Class Enzyme Therapies

Our lead product, ANG003, is a novel, microbially-derived, broad spectrum combination of lipase (for fats), protease (for protein) and amylase (for carbohydrate). This breakthrough oral therapy is currently in clinical trial in people with cystic fibrosis, and has additional therapeutic potential in gastrointestinal disease and digestive cancer.

Malabsorption of macronutrients
leads to devastating consequences:

Debilitating
GI Symptoms

Steatorrhea, constipation, nausea, abdominal pain, bloating, gas, diarrhea

Weight Loss and
Growth Impediment

Weight loss, wasting and fatigue are common and pronounced; independent predictor of survival

Fatty Acid, Carbohydrate,
and Protein Abnormalities

Play a central role in severity of symptoms and disease progression

Increased Morbidity and
Reduced QoL

Worsens clinical outcomes; adds to the overall costs of care and dramatic impact to QoL

Reduced Life-Expectancy

Directly impacts survival in rare disease, cancer and pancreatitis

Metabolic Challenges

Increased inflammation, vitamin deficiencies, reduced bone mineral metabolism and ultimately organ failure

At Anagram, we are developing a deep pipeline of products that use the power of orally delivered enzymes as therapeutics to solve complex problems.

Click the + to get details on each candidate.

Candidate
Indication
Discovery & Optimization
Preclinical
IND
Phase 1
Phase 2
Phase 3
ANG003
Exocrine pancreatic insufficiency; malabsorption syndromes
H1:23
+

New class of enzyme replacement therapy providing unparalleled performance with broad-spectrum composition (lipase for fat, protease for protein, amylase for carbohydrate) to make a life-changing impact for people who require oral ERT.

-
ANG011
Congenital Malabsorptive Syndrome
+

Engineered to break down specific carbohydrates due to enzyme deficiencies to avoid the severe complications associated with carbohydrate malabsorption.

-
ANG021
Malabsorptive Syndrome
+

Engineered to break down specific carbohydrates due to pancreatic dysfunction to avoid the complications associated with carbohydrate malabsorption.

-
ANG031
Congenital Carbohydrate Malabsorption
+

Engineered to break down specific carbohydrates to avoid buildup in the body of toxic complications associated with carbohydrate malabsorption.

-
ANG003
Candidate
Exocrine pancreatic insufficiency;
malabsorption syndromes
Indication
+
Phase 3
H1:23
Phase 2
Phase 1
IND
Preclinical
Discovery & Optimization
-
Phase 3

New class of enzyme replacement therapy providing unparalleled performance with broad-spectrum composition (lipase for fat, protease for protein, amylase for carbohydrate) to make a life-changing impact for people who require oral ERT.

Phase 2
Phase 1
IND
Preclinical
Discovery & Optimization
ANG011
Candidate
Congenital Malabsorptive Syndrome
Indication
+
Phase 3
Phase 2
Phase 1
IND
Preclinical
Discovery & Optimization
-
Phase 3

Engineered to break down specific carbohydrates due to enzyme deficiencies to avoid the severe complications associated with carbohydrate malabsorption.

Phase 2
Phase 1
IND
Preclinical
Discovery & Optimization
ANG021
Candidate
Malabsorptive Syndrome
Indication
+
Phase 3
Phase 2
Phase 1
IND
Preclinical
Discovery & Optimization
-
Phase 3

Engineered to break down specific carbohydrates abnormalities due to pancreatic dysfunction to avoid the complications associated with carbohydrate malabsorption.

Phase 2
Phase 1
IND
Preclinical
Discovery & Optimization
ANG031
Candidate
Congenital Carbohydrate Malabsorption
Indication
+
Phase 3
Phase 2
Phase 1
IND
Preclinical
Discovery & Optimization
-
Phase 3

Engineered to break down specific carbohydrates to avoid buildup in the body of toxic complications associated with carbohydrate malabsorption.

Phase 2
Phase 1
IND
Preclinical
Discovery & Optimization